What J. Lewis Research does

J. Lewis Research, Inc. is a privately held clinical research site organization headquartered in Salt Lake City, Utah, conducting Phase II, III, and IV clinical trials on behalf of pharmaceutical sponsors. The company operates at four integrated family-practice clinic locations across the Salt Lake Valley (Foothill Family Clinic North, Foothill Family Clinic South, Foothill Family Clinic Draper, and Jordan River Family Medicine), with on-site capabilities including x-ray, bone densitometry, EKG, ultrasound, a refrigerated centrifuge, and -20°C/-70°C specimen freezers. One location operates seven days a week with 24/7 on-call coverage, providing accessibility that supports rapid patient recruitment across therapeutic areas such as vaccines (including C. diff and COVID-19), migraine, diabetes, and cardiovascular conditions.

The business model is a professional-services arrangement typical of independent clinical research sites: J. Lewis executes sponsor- or CRO-managed protocols under contract and is compensated per trial through preferred-partner relationships. The company holds preferred-partner status with Parexel, ICON, Merck, and Pfizer, and is recognized as a Pfizer INSPIRE site. All four clinics carry MAGI Blue Ribbon recognition from the MAGI Clinical Research Conference. The leadership team comprises Christopher Mickelson (President), Pamela Ann Iwasaki (Vice President), Brooke Barrick (Clinical Regulatory Manager), and five Principal Investigators with CCRP/FAAFP credentials; the firm employs 11–50 staff and reports having completed over 800 clinical trials across its 30-plus years of operation. Revenue is not publicly disclosed.

Customer concentration is moderate-to-high by structure, with a small number of named enterprise sponsors (Pfizer, Merck, Parexel, ICON) accounting for repeat relationships, though trial-level diversity across 800+ completed studies provides some protocol-level hedging. No AI/ML capabilities, M&A activity, or external funding rounds are evidenced in the input data, and the company has pursued organic geographic expansion only — adding Draper in 2015 as its most recent clinic opening.

Name

J. Lewis Research

Legal name

J. Lewis Research, Inc.

Website

https://jlewisresearch.com

Company type

Private

Founded year

1995

Operating status

Operating

Headcount range

11–50 employees

Short description

J. Lewis Research is a privately held Salt Lake City-based clinical research site organization conducting Phase II–IV trials for pharmaceutical sponsors, operating across four integrated family-practice clinics with five Principal Investigators and 30+ years of experience.

Ownership category

akta.pro rank

Product category

Clinical Research Site Services

NAICS

Scientific Research and Development Services (5417), Medical and Diagnostic Laboratories (62151)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical Trial Site Operations & Study Coordination (HLAGACAE)

akta.pro secondary industries

Patient Recruitment, Site Feasibility & Trial Enablement CROs (HLAGAAAI), Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)

Keywords

• Clinical trial services
• Pharmaceutical research
• Clinical research site
• Phase III trials
• Vaccine research

Headquarters

HQ city

Salt Lake City

HQ country

United States

HQ region

North America

Offices5 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Clinical Trial Site Services: Contract research organization (CRO) providing site-level clinical trial services to pharmaceutical companies. Revenue is generated through conducting Phase II, III, and IV clinical trials under contract with sponsors and CRO partners.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

J. Lewis Research is a clinical research organization that conducts Phase II, III, and IV clinical trials at the site level for pharmaceutical companies and CROs. Operating from four family practice clinic locations in the Salt Lake Valley, they deliver site-based trial execution including on-site labs, imaging, specimen processing, and patient recruitment across therapeutic areas such as vaccines, infectious disease, migraine, diabetes, and cardiovascular conditions.

Product overview

J. Lewis Research is a clinical research organization conducting Phase II, III, and IV clinical trials for the pharmaceutical industry. The company operates at four family practice clinic locations in the Salt Lake City area, offering clinical trial services that include C. Diff Vaccine studies, Migraine research studies, and COVID-19 Vaccine trials. The company has completed over 800 clinical trials during its 30+ years of operation.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Trial Research Services Site-based execution of Phase II, III, and IV clinical trials for pharmaceutical sponsors and CROs across therapeutic areas including vaccines, infectious disease, migraine, diabetes, and cardiovascular conditions.
• C. Diff Vaccine Studies Clinical trials focused on vaccine development for Clostridioides difficile infection prevention, conducted at J. Lewis Research's Salt Lake Valley sites.
• Migraine Research Studies Clinical trials investigating treatments for migraine conditions in both adult and pediatric populations, conducted at J. Lewis Research's family practice clinic sites.
• COVID-19 Vaccine Trials Clinical trials evaluating COVID-19 vaccine candidates for efficacy and safety, conducted by J. Lewis Research for pharmaceutical sponsors.

Quantifiable outcome

• Completed over 800 clinical trials
• +1 more outcomes

Named customers4 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Four partnerships are on record, tiered core.

• PfizercoreStrategic or Co-development PartnerPreferred partner status and recognized as Pfizer INSPIRE sites, conducting Phase II, III, and IV clinical trials for Pfizer pharmaceutical products.
• MerckcoreStrategic or Co-development PartnerPreferred partner conducting clinical trials for Merck pharmaceutical products.
• ParexelcoreStrategic or Co-development PartnerPreferred partner CRO managing clinical trial operations; J. Lewis Research serves as clinical trial site for Parexel-managed studies.
• ICON plccoreStrategic or Co-development PartnerPreferred partner CRO; Dr. Dan C. Henry has worked with ICON as a Principal Investigator.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Elligo Health Research: Multi-site clinical research site network providing Phase II-IV trial execution through affiliated physician practices; closely comparable operating model to J. Lewis Research's family-clinic-anchored site strategy but at national scale.
• Velocity Clinical Research: Operator of a consolidated network of clinical research sites across the U.S. conducting Phase II-IV trials for pharma sponsors; directly comparable service offering and patient-recruitment model.
• Meridian Clinical Research: Independent clinical research site network with multi-specialty sites conducting Phase II-IV trials; same therapeutic breadth and sponsor relationships as J. Lewis Research.
• DM Clinical Research: Independent clinical trial site network operating across multiple U.S. metros; directly comparable Phase II-IV site services for pharmaceutical sponsors.
• Accel Research Sites: Multi-site clinical research organization conducting Phase I-IV trials through affiliated physician practices; same business model anchored in community-based physician clinics.
• Centricity Research: Clinical research site network operating across North America with Phase II-IV capabilities for pharma sponsors; comparable operating model and therapeutic-area breadth.

Broad incumbents

• CenExel: Large multi-site clinical research organization with specialized Phase I-IV capabilities including CNS and analgesia; broader portfolio than J. Lewis Research but directly competing for Phase II-IV study allocations.
• Parexel: Global CRO that J. Lewis Research already partners with as a preferred site; comparable as a major counterparty in the same Phase II-IV trial ecosystem, though operating as the sponsor-facing CRO rather than as a site.
• ICON plc: Global CRO and existing preferred-partner of J. Lewis Research; relevant as a customer-side incumbent in the same Phase II-IV trial value chain.

Emerging players

• Javara Inc. Integrated clinical research organization embedding trials within partnered health systems; comparable in concept (clinics-as-sites) but operating through a different partnership model with health systems.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/jlewisresearch
• Facebookfacebook.com/jlewisresearch

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about J. Lewis Research